Whalesbook
Valuation Gains Mask Profit Woes
Krsnaa Diagnostics reported a net profit of ₹41.70 crore for Q4 FY26, a significant year-on-year increase. However, this figure includes a ₹22.20 crore fair valuation gain from its associate company, Apulki Healthcare. Excluding this one-time gain, the adjusted profit stood at ₹10.20 crore, highlighting pressure on underlying operational earnings. The company's revenue for the quarter was ₹192.60 crore, falling about 7% short of analyst estimates. The stock experienced notable volatility following the results, reflecting investor uncertainty.
High Capex Plans Face Execution Hurdles
Looking ahead, Krsnaa Diagnostics plans to invest ₹530 crore in fixed assets during FY27, focusing on expanding radiology services and its Rajasthan project. However, the company has already revised its revenue guidance for the Rajasthan project downwards to ₹100-150 crore. This intensive capital expenditure strategy, particularly for its radiology-heavy infrastructure, requires substantial upfront investment, which is about 2.5 times higher than typical pathology businesses. This model, while creating a competitive edge in public tenders, also exposes the company to margin risks if operations do not scale as planned.
Stagnant Retail Segment and Stock Volatility
Further concerns arise from the company's retail B2C segment, which generated ₹15.80 crore in revenue sequentially, showing little to no growth despite a large network. Krsnaa Diagnostics also carries a high beta, making its stock particularly sensitive to market downturns. Management expects temporary pressure on EBITDA margins in Q1 FY27 due to increased staffing costs, suggesting a challenging near-term outlook for margin improvement.
Cautious Optimism Amidst Mixed Signals
Despite these challenges, institutional sentiment remains cautiously optimistic, with expectations of long-term value creation from Krsnaa's niche in radiology-led public-private partnerships. The key for the company in FY27 will be stabilizing the Rajasthan project and achieving significant growth from its B2C segment, moving beyond reliance on balance sheet adjustments to meet investor expectations.